Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer (SWIFT)
2026년 9월 9일 업데이트: Aparna A. Kamat, The Methodist Hospital Research Institute
SEMAGLUTIDE, WEIGHT LOSS, AND INTRAUTERINE THERAPY FOR FERTILITY-SPARING AND CONSERVATIVE TREATMENT FOR ENDOMETRIAL ATYPICAL HYPERPLASIA AND EARLY-STAGE, GRADE 1 ENDOMETRIOID ENDOMETRIAL CANCER
The goal of this clinical trial is to learn if a combination treatment of a hormonal intrauterine device (LNG-IUD), semaglutide, and a structured weight loss program can treat endometrial atypical hyperplasia or grade 1 endometrioid endometrial cancer while preserving fertility in women of reproductive age with endometrial atypical hyperplasia (EAH) or FIGO grade 1 endometrioid endometrial cancer who wish to preserve their fertility. The main questions it aims to answer are:
- What proportion of participants achieve a complete pathological response after treatment?
- How durable is the response at 12 months?
- What effect does the treatment have on metabolic outcomes (weight, BMI, HbA1c) and quality of life?
Participants will:
- Receive an LNG-IUD
- Receive semaglutide 2.4mg
- Participate in a structured weight loss program
- Undergo hysteroscopy with endometrial sampling to assess treatment response
- Complete quality-of-life assessments at baseline, 6 months, and 12 months
연구 개요
상태
상태
아직 모집하지 않음
정황
정황
개입 / 치료
개입 / 치료
연구 유형
연구 유형
중재적
등록 (추정된)
등록
48
단계
단계
- 2 단계
연락처 및 위치
이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.
연구 장소
-
-
Texas
-
Houston, Texas, 미국, 77030
- Houston Methodist at The Medical Center
-
연락하다:
- Jaya S. Kamath, MS
- 전화번호: 713-441-6616
- 이메일: jskamath@houstonmethodist.org
-
Houston, Texas, 미국, 77030
- Houston Methodist Sugar Land
-
연락하다:
- Jaya S. Kamath, MS
- 전화번호: 713-441-6616
- 이메일: jskamath@houstonmethodist.org
-
Houston, Texas, 미국, 77030
- Houston Methodist Willowbrook
-
연락하다:
- Jaya S. Kamath, MS
- 전화번호: 713-441-6616
- 이메일: jskamath@houstonmethodist.org
-
Houston, Texas, 미국, 77030
- Houston Methodist Woodlands
-
연락하다:
- Jaya S. Kamath, MS
- 전화번호: 713-441-6616
- 이메일: jskamath@houstonmethodist.org
-
-
참여기준
연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.
자격 기준
자격 기준
공부할 수 있는 나이
- 성인
- 고령자
건강한 자원 봉사자를 받아들입니다
아니
설명
Inclusion Criteria:
- Histological Diagnosis: Histologically confirmed endometrial atypical hyperplasia or FIGO grade 1 endometrioid Endometrial Cancer
Imaging eligibility (for patients with endometrial cancer):
- Depth of myometrial invasion <50% confirmed by MRI or disease limited to the endometrium
- No evidence of extrauterine or metastatic disease on imaging.
Treatment Rationale (at least one of the following must apply):
- Desire for future fertility: Patient expresses a documented desire to preserve the uterus and future reproductive function, with explicit acknowledgment that fertility-sparing treatment is not standard of care for endometrial cancer.
- Medical inoperability: patients are considered a poor surgical candidate due to:
i. Class III obesity (BMI ≥40 kg/m²); or ii. ASA Physical Status Classification score ≥3.
- Metabolic Profile: BMI ≥ 30 kg/m², or BMI 27-29.9 kg/m² with at least one weight-related comorbidity (hypertension, type 2 diabetes mellitus, dyslipidemia, obstructive sleep apnea, or non-alcoholic fatty liver disease).
Progestin washout: patients with prior progestin exposure are eligible provided the following minimum washout periods have been observed.
- Oral progestins: 7 days
- Injectable, short acting: 14 days
- Injectable, long acting: 6 months
- Contraceptive implant: 28 days
- LNG-IUD: 7 days after removal
Exclusion Criteria:
- Age ≥18 years
- Negative pregnancy test at screening
- Ability to provide written informed consent and comply with study procedures
- Willingness to undergo genetic counseling and MMR/IHC tumor profiling
- Willingness and ability to participate in a structured weight loss program, including attendance at counseling sessions (in person or virtual) and adherence to dietary and physical activity goals.
공부 계획
이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.
연구는 어떻게 설계됩니까?
디자인 세부사항
- 주 목적: 치료
- 할당: 해당 없음
- 중재 모델: 단일 그룹 할당
- 마스킹: 없음(오픈 라벨)
팔의 수
1
무기와 개입
참가자 그룹 / 팔참가자 그룹 / 팔 |
개입 / 치료개입 / 치료 |
|---|---|
|
실험적: Combination Fertility-Sparing Treatment
Participants will receive a three-component combination intervention consisting of: (1) a levonorgestrel-releasing intrauterine device (LNG-IUD), inserted at baseline; (2) semaglutide 2.4 mg, administered per standard dosing schedule; and (3) a structured weight loss program.
Participants will undergo hysteroscopy with endometrial sampling to assess pathological response.
Treatment will be administered for 6 months of active intervention, followed by a 6-month follow-up period.
|
Semaglutide 2.4 mg administered subcutaneously once weekly, following standard dose-escalation protocol, for the duration of the 6-month active treatment period.
Used off-label in this trial for its metabolic effects in combination with LNG-IUD, rather than as monotherapy for weight loss.
Levonorgestrel-releasing intrauterine device inserted at study baseline and maintained through the active treatment and follow-up periods, providing continuous local progestin delivery to the endometrium in combination with systemic semaglutide.
A structured, protocol-defined weight loss program combining dietary counseling and physical activity guidance, delivered concurrently with pharmacologic and device-based treatment to support metabolic response, distinct from weight loss achieved through semaglutide alone.
|
연구는 무엇을 측정합니까?
주요 결과 측정
주요 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Pathological Response Rate
기간: 6 months
|
Pathological Response Rate (PRR) defined as the rate of regression of atypical hyperplasia or carcinoma on histopathological examination of the 6-month (end-of-treatment) hysteroscopic sample
|
6 months
|
2차 결과 측정
2차 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Time to response
기간: 12 months
|
Time to response in months from treatment initiation to first documented histopathological regression
|
12 months
|
|
Adverse events
기간: 12 months
|
Incidence and severity of adverse events, graded per NCI-CTCAE v5.0, including drug-related (semaglutide) and device-related (LNG-IUD) events
|
12 months
|
|
Durable response rate
기간: 12 months
|
The proportion of participants who achieve a complete pathological response and maintain that response, without evidence of disease recurrence or progression, through 12 months following treatment initiation.
Durable response will be assessed via hysteroscopy with endometrial sampling.
|
12 months
|
|
Disease progression rate
기간: 12 months
|
The proportion of participants who experience disease progression, defined as an increase in histologic grade or stage of endometrial atypical hyperplasia or endometrial cancer, without ever achieving a complete pathological response, assessed through 12 months from treatment initiation.
Disease status will be assessed via hysteroscopy with endometrial sampling.
|
12 months
|
|
Recurrence rate
기간: 12 months
|
The proportion of participants who experience recurrence of endometrial atypical hyperplasia or endometrial cancer following an initial complete pathological response, assessed through 12 months from treatment initiation.
Disease status will be assessed via hysteroscopy with endometrial sampling.
|
12 months
|
기타 결과 측정
기타 결과 측정
결과 측정 |
측정값 설명 |
기간 |
|---|---|---|
|
Body weight change
기간: 12 months
|
Change in body weight, measured in kilograms, from baseline to 6 and 12 months following treatment initiation.
|
12 months
|
|
Body mass index (BMI) change
기간: 12 months
|
Change in body mass index (BMI), calculated as weight in kilograms divided by height in meters squared, from baseline to 6 and 12 months following treatment initiation.
|
12 months
|
|
Waist circumference change
기간: 12 months
|
Change in waist circumference, measured in centimeters, from baseline to 6 and 12 months following treatment initiation.
|
12 months
|
|
Hip circumference change
기간: 12 months
|
Change in hip circumference, measured in centimeters, from baseline to 6 and 12 months following treatment initiation.
|
12 months
|
|
Waist-to-hip ratio change
기간: 12 months
|
Change in waist-to-hip ratio, calculated as waist circumference divided by hip circumference, from baseline to 6 and 12 months following treatment initiation.
|
12 months
|
|
Glycated Hemoglobin change
기간: 12 months
|
Change in glycated hemoglobin (HbA1c), measured as a percentage, from baseline to 6 and 12 months following treatment initiation.
|
12 months
|
|
Weight-Related Quality of Life (WRQOL)
기간: 12 months
|
Change in weight-related quality of life, assessed using a validated WRQOL questionnaire, from baseline to 6 and 12 months following treatment initiation.
|
12 months
|
|
Health-Related Quality of Life (HRQOL)
기간: 12 months
|
Change in health-related quality of life, assessed using a validated HRQOL questionnaire, from baseline to 6 and 12 months following treatment initiation.
|
12 months
|
공동 작업자 및 조사자
여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.
수사관
수사관
- 수석 연구원: Aparna A. Kamat, MD, The Methodist Hospital Research Institute
간행물 및 유용한 링크
연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.
일반 간행물
- Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, McGowan BM, Rosenstock J, Tran MTD, Wadden TA, Wharton S, Yokote K, Zeuthen N, Kushner RF; STEP 1 Study Group. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021 Mar 18;384(11):989-1002. doi: 10.1056/NEJMoa2032183. Epub 2021 Feb 10.
- Wang L, Xu R, Kaelber DC, Berger NA. Glucagon-Like Peptide 1 Receptor Agonists and 13 Obesity-Associated Cancers in Patients With Type 2 Diabetes. JAMA Netw Open. 2024 Jul 1;7(7):e2421305. doi: 10.1001/jamanetworkopen.2024.21305.
- Dai H, Li Y, Lee YA, Lu Y, George TJ, Donahoo WT, Lee KP, Nakshatri H, Allen J, Guo Y, Sun RC, Guo J, Bian J. GLP-1 Receptor Agonists and Cancer Risk in Adults With Obesity. JAMA Oncol. 2025 Oct 1;11(10):1186-1193. doi: 10.1001/jamaoncol.2025.2681.
- Podder V, Coleman RL, Hagemann AR, Singhania P, Powell MA, Herzog TJ, Slomovitz BM. Repositioning GLP-1 Receptor Agonists in Endometrial Cancer: Molecular Rationale, Preclinical Insights, and Translational Opportunities. Clin Cancer Res. 2026 Feb 4;32(3):447-454. doi: 10.1158/1078-0432.CCR-25-2819.
- Peevey JF, Seagle BL, Maniar KP, Kim JJ. Association of body mass index with ER, PR and 14-3-3sigma expression in tumor and stroma of type I and type II endometrial carcinoma. Oncotarget. 2017 Jun 27;8(26):42548-42559. doi: 10.18632/oncotarget.17209.
- Zhang Z, Dong L, Sui L, Yang Y, Liu X, Yu Y, Zhu Y, Feng Y. Metformin reverses progestin resistance in endometrial cancer cells by downregulating GloI expression. Int J Gynecol Cancer. 2011 Feb;21(2):213-21. doi: 10.1097/IGC.0b013e318207dac7.
- Burzawa JK, Schmeler KM, Soliman PT, Meyer LA, Bevers MW, Pustilnik TL, Anderson ML, Ramondetta LM, Tortolero-Luna G, Urbauer DL, Chang S, Gershenson DM, Brown J, Lu KH. Prospective evaluation of insulin resistance among endometrial cancer patients. Am J Obstet Gynecol. 2011 Apr;204(4):355.e1-7. doi: 10.1016/j.ajog.2010.11.033. Epub 2011 Feb 16.
- Zhu XX, Feng ZH, Liu LZ, Zhang Y. Liraglutide suppresses the proliferation of endometrial cancer cells through the adenosine 5'-monophosphate (AMP)-activated protein kinase signaling pathway. Chin Med J (Engl). 2021 Jan 19;134(5):576-578. doi: 10.1097/CM9.0000000000001363. No abstract available.
- Wichmann IA, Cuello MA. Obesity and gynecological cancers: A toxic relationship. Int J Gynaecol Obstet. 2021 Oct;155 Suppl 1(Suppl 1):123-134. doi: 10.1002/ijgo.13870.
- Kailasam A, Cucinella G, Fought AJ, Cliby W, Mariani A, Glaser G, Langstraat C. Nonsurgical management of early-stage endometrial cancer due to obesity: a survey of the practice patterns of current Society of Gynecologic Oncology members. Gynecol Oncol Rep. 2023 Oct 4;50:101280. doi: 10.1016/j.gore.2023.101280. eCollection 2023 Dec.
- Kong W, Deng B, Shen X, John C, Haag J, Sinha N, Lee D, Sun W, Chen S, Zhang H, Clontz A, Hursting SD, Zhou C, Bae-Jump V. Tirzepatide as an innovative treatment strategy in a pre-clinical model of obesity-driven endometrial cancer. Gynecol Oncol. 2024 Dec;191:116-123. doi: 10.1016/j.ygyno.2024.10.004. Epub 2024 Oct 10.
- Westin SN, Fellman B, Sun CC, Broaddus RR, Woodall ML, Pal N, Urbauer DL, Ramondetta LM, Schmeler KM, Soliman PT, Fleming ND, Burzawa JK, Nick AM, Milbourne AM, Yuan Y, Lu KH, Bodurka DC, Coleman RL, Yates MS. Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer. Am J Obstet Gynecol. 2021 Feb;224(2):191.e1-191.e15. doi: 10.1016/j.ajog.2020.08.032. Epub 2020 Aug 15.
- Janda M, Robledo KP, Gebski V, Armes JE, Alizart M, Cummings M, Chen C, Leung Y, Sykes P, McNally O, Oehler MK, Walker G, Garrett A, Tang A, Land R, Nicklin JL, Chetty N, Perrin LC, Hoet G, Sowden K, Eva L, Tristram A, Obermair A. Complete pathological response following levonorgestrel intrauterine device in clinically stage 1 endometrial adenocarcinoma: Results of a randomized clinical trial. Gynecol Oncol. 2021 Apr;161(1):143-151. doi: 10.1016/j.ygyno.2021.01.029.
연구 기록 날짜
이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.
연구 주요 날짜
연구 시작 (추정된)
연구 시작
2027년 1월 1일
기본 완료 (추정된)
기본 완료
2028년 12월 31일
연구 완료 (추정된)
연구 완료
2031년 12월 31일
연구 등록 날짜
최초 제출
최초 제출
2026년 9월 9일
QC 기준을 충족하는 최초 제출
QC 기준을 충족하는 최초 제출
2026년 9월 9일
처음 게시됨 (실제)
처음 게시됨
2026년 9월 15일
연구 기록 업데이트
마지막 업데이트 게시됨 (실제)
마지막 업데이트 게시됨
2026년 9월 15일
QC 기준을 충족하는 마지막 업데이트 제출
QC 기준을 충족하는 마지막 업데이트 제출
2026년 9월 9일
마지막으로 확인됨
마지막으로 확인됨
2026년 8월 1일
추가 정보
이 연구와 관련된 용어
키워드
추가 관련 MeSH 약관
기타 연구 ID 번호
기타 연구 ID 번호
- PRO00043004
개별 참가자 데이터(IPD) 계획
개별 참가자 데이터(IPD)를 공유할 계획입니까?
예
IPD 계획 설명
De-identified individual participant data, including the study protocol and statistical analysis plan, will be made available to researchers who provide a methodologically sound proposal, beginning 12 months after publication of the primary results and ending 36 months after publication.
Data will be shared for the purpose of achieving the aims outlined in the approved proposal, following execution of a data access agreement.
IPD 공유 기간
Data will become available beginning 12 months after publication of the primary study results and will remain available for 36 months thereafter.
IPD 공유 액세스 기준
De-identified individual participant data, including the study protocol, statistical analysis plan, and informed consent form, will be available to researchers who provide a scientifically sound proposal for data use.
Requests should be directed to the principal investigator.
Proposals will be reviewed to confirm that the intended use is consistent with the original trial objectives and applicable data protection regulations.
Approved requesters will be required to sign a data access agreement prior to receiving data.
Access will be granted for the purpose of achieving the aims outlined in the approved proposal.
IPD 공유 지원 정보 유형
- 연구_프로토콜
- 수액
- ICF
- CSR
약물 및 장치 정보, 연구 문서
미국 FDA 규제 의약품 연구
예
미국 FDA 규제 기기 제품 연구
예
미국에서 제조되어 미국에서 수출되는 제품
아니
이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .